The Journal of antimicrobial chemotherapy
-
J. Antimicrob. Chemother. · Dec 2020
Multicenter Study Observational StudyDe-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock.
De-escalation of empirical antimicrobial therapy, a key component of antibiotic stewardship, is considered difficult in ICUs with high rates of antimicrobial resistance. ⋯ In ICUs with high levels of antimicrobial resistance, feasibility of antimicrobial de-escalation was limited because of the multi-resistant pathogens isolated. However, when de-escalation was feasible and applied, it was associated with lower mortality.
-
J. Antimicrob. Chemother. · Nov 2020
Observational StudyEffectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.
Remdesivir is a prodrug with in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Its clinical efficacy in patients with COVID-19 under mechanical ventilation remains to be evaluated. ⋯ In this study the mortality rate of patients with COVID-19 under mechanical ventilation is confirmed to be high. The use of remdesivir was associated with a significant beneficial effect on survival.
-
J. Antimicrob. Chemother. · Nov 2020
Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey.
Antibiotics may be indicated in patients with COVID-19 due to suspected or confirmed bacterial superinfection. ⋯ The study revealed widespread broad-spectrum antibiotic use in patients with COVID-19. Implementation of antimicrobial stewardship principles is warranted to mitigate the negative consequences of antibiotic therapy.
-
J. Antimicrob. Chemother. · Oct 2020
Case ReportsPharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Remdesivir is a prodrug of the nucleoside analogue GS-441524 and is under evaluation for treatment of SARS-CoV-2-infected patients. ⋯ We report the first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients. Further study of the pharmacokinetic profile of remdesivir, GS-441524 and the intracellular triphosphate form are required.